Tirzepatide weight loss results by dose: 5, 10, and 15 mg
Tirzepatide's weight loss scales clearly with dose, and SURMOUNT-1 quantified exactly how much. Here's what to expect at 5, 10, and 15 mg — and why the top dose is where the drug shines.
The dose-response, quantified
SURMOUNT-1 randomized over 2,500 adults with obesity and no diabetes to three tirzepatide doses or placebo. The result was one of the clearest dose-response relationships in weight-loss medicine: each step up delivered meaningfully more loss.
At 15 mg, average loss was about 20.9% — roughly a fifth of body weight, a magnitude previously associated more with bariatric surgery than with medication.
Because the response scales so cleanly, the dose you ultimately tolerate has a large effect on your result. That's also why cost structure matters: on dose-tiered plans, the most effective dose is often the most expensive, so annualized maintenance cost is the honest number to compare.
How many reach major milestones
Beyond averages, SURMOUNT-1 reported the share of patients hitting key thresholds. At 15 mg, most participants lost at least 15% of body weight, and a substantial fraction lost 20% or more — far beyond what earlier weight-loss drugs achieved.
This matters because clinically meaningful benefits — for blood pressure, glucose, sleep apnea, and joint load — scale with the amount of weight lost.
Individual results vary around these averages. Adherence, the dose you can tolerate, nutrition, and activity all shift where you land, and a minority of people respond less strongly — which is worth discussing with your clinician rather than assuming the average is guaranteed.
| Threshold | % reaching at 15 mg |
|---|---|
| ≥5% loss | ~91% |
| ≥10% loss | ~84% |
| ≥15% loss | ~71% |
| ≥20% loss | ~57% |
Tirzepatide vs semaglutide
Tirzepatide's dual GIP/GLP-1 mechanism appears to give it an edge. In the head-to-head SURMOUNT-5 trial, tirzepatide produced about 20.2% loss versus 13.7% for semaglutide over 72 weeks — a clear separation.
That doesn't make semaglutide obsolete; cost, tolerability, and cardiovascular evidence still favor it for some patients. But for maximum weight loss, the data points to tirzepatide.
The choice between the two is rarely just about peak efficacy. Semaglutide has the landmark SELECT cardiovascular outcome data, while tirzepatide leads on weight loss and has unique approvals like obstructive sleep apnea — so the 'better' drug genuinely depends on your goals and health profile.
The bottom line
Tirzepatide's defining feature is the size of the effect at higher doses — roughly a fifth of body weight at 15 mg in SURMOUNT-1. If maximum weight loss is your priority and you tolerate the titration, it's the most powerful option currently available through telehealth.
That said, the top dose is also where tiered pricing bites hardest, so map out the annual cost at 15 mg before you start. A flat-rate program that holds one price across the ladder can be dramatically cheaper over a year than a plan whose price climbs with every dose increase.
Whatever route you choose, the fundamentals hold: tirzepatide therapy works best as part of a sustainable plan pairing the medication with protein-forward nutrition, resistance training, and consistent clinical follow-up. In every pivotal trial, the people who reached and held their effective dose — and stayed on treatment long enough for the biology to work — captured the largest, most durable results, which is why predictable cost and genuine clinician support belong in the decision alongside the sticker price.
How we verify pricing & evidence
We source pricing from the RangeYourself independent GLP-1 telehealth index, human-verified against live provider pages July 1–3, 2026 and used under CC-BY-4.0 with attribution. The clinical numbers come from the published STEP and SURMOUNT trial programs and peer-reviewed cardiovascular and body-composition research. Because both prices and evidence evolve, treat these as a July 2026 snapshot and verify with the provider first; compounded GLP-1 products are not FDA-approved.
Frequently asked questions
In SURMOUNT-1, average loss was ~15.0% at 5 mg, ~19.5% at 10 mg, and ~20.9% at 15 mg over 72 weeks. Higher doses drive more loss, and individual results vary.
For peak weight loss, yes — SURMOUNT-5 head-to-head showed 20.2% vs 13.7%. Semaglutide still leads on cardiovascular outcome evidence, so the best choice depends on your goals.
Not necessarily. Many people get strong results at 10 mg. Your clinician titrates based on response and tolerability, and lower doses can also cost less on tiered plans.
Appetite changes often appear within weeks; the SURMOUNT-1 results reflect 72 weeks of treatment, with the steepest loss in the middle of that period.
Key takeaways
- SURMOUNT-1: ~15.0% (5 mg), ~19.5% (10 mg), ~20.9% (15 mg) weight loss over 72 weeks.
- The dose-response is steep, so the tolerated dose strongly shapes your result.
- At 15 mg, ~71% of patients lost ≥15% and ~57% lost ≥20% of body weight.
- Head-to-head, tirzepatide beat semaglutide (20.2% vs 13.7%) in SURMOUNT-5.